Business Wire

Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors

Del

Kite, a Gilead Company (Nasdaq: GILD), today announced results from an ongoing Phase 1 study conducted by the National Cancer Institute (NCI) showing that clinical responses were observed with investigational T cell receptor (TCR) cell therapy targeting human papillomavirus type 16 (HPV-16) E7 in solid tumor cancers caused by HPV. These findings were presented today in a poster session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract #3043).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180604005335/en/

TCR therapy is a type of personalized immunotherapy designed to activate the immune system's ability to recognize and target specific tumors. TCR therapy involves engineering an individual’s own T cells to express naturally occurring receptors that can recognize specific tumor antigens. Epithelial cancers caused by HPV, including cervical, head and neck, anal and genital cancers, contain a protein called E7 inside tumor cells. Patients with these tumors whose cancers have relapsed and/or are refractory to standard therapy are currently incurable.

In this study, eight patients with metastatic HPV-16 cancers received a single infusion of gene-engineered E7 T cells at one of three dose levels. Patients had received between three and seven prior lines of systemic cancer therapy. In the initial six patients, the E7 TCR was expressed by 90-99 percent of the infused T cells, and E7 T cells were detectable in the peripheral blood six weeks following treatment. The study is ongoing.

Partial responses (Response Evaluation Criteria in Solid Tumors (RECIST); RECIST 1.1) were observed in three out of the seven evaluable patients and another two patients had stable disease. To date, the responses have lasted as long as nine months and have occurred in patients with vulvar, oropharyngeal and anal cancer. Two of these patients had been previously treated with anti-PD1 checkpoint blockade.

“Metastatic HPV-cancers are incurable and poorly addressed by standard therapies,” said Christian S. Hinrichs, MD, Lasker Clinical Research Scholar at the Center for Cancer Research’s Experimental Transplantation and Immunology Branch (ETIB) at the NCI and lead study investigator. “The early results from this Phase 1 trial support the continued evaluation of TCR therapy in HPV-associated cancers.”

No dose-limiting toxicity occurred. The most common grade 3 or higher adverse events were anemia, lymphopenia, leukopenia and neutropenia, each of which occurred in all seven evaluable patients.

The trial is part of a Cooperative Research and Development Agreement (CRADA) between the ETIB of the NCI and Kite to further the research and clinical development of TCR product candidates for the treatment of HPV-associated cancers. Patients interested in enrolling in the 16-C-0154 clinical trial can call the National Cancer Institute’s toll-free number 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615) or visit https://trials.cancer.gov.

HPV has a causal role in nearly all cervical cancers, and in many head and neck and anogenital malignancies. HPV-16 is the most commonly found strain in these cancers. More than 33,000 cases of HPV-associated cancers are diagnosed each year in the U.S. and more than 10,000 deaths are attributed to the disease, according to the Centers for Disease Control and Prevention. Current therapies for HPV-associated tumors have low response rates and poor response duration.

“Findings from this Phase 1 study validate the E7 protein as a viral target for TCR therapy,” said Alessandro Riva, MD, Gilead’s Executive Vice President, Oncology Therapeutics & Head, Cell Therapy. “We plan to submit an IND for our TCR candidate, KITE-439, for HPV-16 E7 solid tumors by the end of the year, and we continue to explore other potential TCR therapy candidates for a variety of cancers in partnership with the NCI.”

KITE-439 is investigational and has not been proven safe or efficacious.

About Kite

Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. For more information on Kite, please visit www.kitepharma.com.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from additional clinical trials involving KITE-439 for the treatment of HPV-16 E7 solid tumors or other HPV-associated cancers. In addition, Kite may be unable to submit the IND for KITE-439 in the currently anticipated timelines or at all. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation to update any such forward-looking statements.

For more information on Kite, please visit the company’s website at  www.kitepharma.com . Learn more about Gilead at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contact information

Gilead Sciences, Inc.
Investors
Sung Lee, 650-524-7792
or
Media
Nathan Kaiser, 650-522-1853

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Yamaha Motor Outline of Long-term Vision & New Medium-term Management Plan11.12.2018 06:05Pressemelding

Yamaha Motor Co., Ltd. (TOKYO:7272) announced today that it has formulated its long-term vision until 2030, and a New Medium-term Management Plan for the three-year period starting in 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181210005244/en/ (Photo: Business Wire) For its long-term vision, Yamaha Motor has created the slogan “ART for Human Possibilities” and devised a growth strategy heading for 2030. For increasingly diversifying people's values and the environment around societies, the Company will implement its growth strategies while promoting solutions to social issues based on its own historical values. While maintaining the earning power from existing businesses, the new medium-term management plan will allocate resources to strategic growth areas such as new business, and work toward achieving consolidated net sales of 2-trillion yen and a consolidated operating income of 180 billion yen. View source vers

Egon Zehnder Global Board Diversity Tracker Suggests Gender Parity in the Boardroom May Never Be Achieved11.12.2018 06:01Pressemelding

Egon Zehnder, the world's leadership advisory firm, today released the results of its 2018 Global Board Diversity Tracker. The study shows the accelerating growth seen in female directors in Western Europe is now levelling off, and growth elsewhere remains sluggish, suggesting gender parity on boards may never be reached at the current pace. The research, examining data from 1610 public companies with market caps above €7bn in 44 different countries, shows that despite the slow improvement in the number of women on boards, nearly three quarters of all new board positions worldwide still go to men. Jill Ader, Chairwoman of Egon Zehnder, said: “We need diversity, but it’s simply not happening fast enough. New voices and perspectives are essential to unlock the transformational capabilities that businesses tell us they need. Companies - starting from the very top - have to recognize the impact that a critical mass of women on the board and the executive committee makes and take the steps

Rootstock Software Announces New International Channel Partners11.12.2018 06:00Pressemelding

Rootstock Software, a leading cloud Enterprise Resource Planning (ERP) provider for manufacturing, distribution and supply chain organizations on the Salesforce Platform, announced today that the company is continuing to experience significant international growth with the signing of several new partners. These partners will provide Rootstock customers in Europe, the Middle East and Southeast Asia with consulting and implementation services for the company’s Cloud ERP solution. Rootstock Cloud ERP is a flexible, modern and digitally connected ERP solution that provides organizations with real-time management across their entire business, including manufacturing, distribution, supply chain and finance operations. Rootstock’s channel partners will help customers achieve their digital transformation and business goals by leveraging Rootstock to better connect customers, suppliers and employees. When combined with Salesforce, Rootstock Cloud ERP customers enjoy a 360-degree view of all cus

Cred Opens Its Platform to Developers and Businesses10.12.2018 20:21Pressemelding

Cred, the leading provider of crypto-backed lending with over $300 million in credit facilities, today announced the launch of CredX, Cred’s developer platform, enabling any company or developer to turn their products into powerful financial applications for their customers. Crypto exchanges, crypto wallets, miner service providers, even traditional financial institutions have the ability to access Crypto Lending as a Service (CLaaS™) and create a rich set of customer experiences for their customers. “Lending and Earning Crypto are hard businesses to get right, particularly in a bear market,” said Dan Schatt, Co-Founder of Cred and the Universal Protocol Alliance. “A crypto custodian, wallet, merchant or exchange business can now offer their customers compelling credit and treasury management features built directly into their own apps, powered by Cred. Businesses can choose to use their own balance sheets, or leverage Cred’s to provide credit and earning services to generate revenue,

Axonics® Announces Publication of NICE Briefing10.12.2018 16:03Pressemelding

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today the publication of a Medtech Innovation Briefing by The National Institute for Health and Care Excellence (“NICE”) following a careful review of the innovations offered by the Axonics System. The NICE Medtech Innovation Briefing entitled: “Axonics rechargeable sacral neuromodulation system for overactive bladder and faecal incontinence,” describes published clinical evidence on the Axonics r-SNM System®, confirming efficacy as well as the potential positive economic impact that is possible by the use of the Axonics system in the United Kingdom. The Axonics r-SNM System is the first rechargeable Sacral Neuromodulation system approved for sale in Europe and commercially available to all hospitals and clinics in the U.K. for patients

The Largest Blockchain Conference in Asia to Be Held 30–31 January in Yokohama, Japan10.12.2018 15:00Pressemelding

The Global Blockchain Association (Shimizu Building 6F, 3-19 Hayabusacho, Chiyoda-ku, Tokyo, President: Toshikazu Masuyama) is proud to host the largest blockchain conference in Asia: The Japan Blockchain Conference (JBC) – 2019 Yokohama, to be held on 30 and 31 January at Pacifico Yokohama. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181210005057/en/ The Japan Blockchain Conference (JBC) - 2019 Yokohama (Graphic: Business Wire) The conference will host top companies and organizations from Japan and abroad who represent the future of the rapidly growing blockchain space. This is the place where the leaders of blockchain and crypto can interact, form partnerships, and showcase their leading technologies and developments. We are actively looking for companies to join the best of the blockchain industry and exhibit at our conference. More details can be found here: http://japan-blockchain-c.com/en/ We welcome a wide range of